Oral Administration of Live and Dead Cells of Lactobacillus sakei proBio65 Alleviated Atopic Dermatitis in Children and Adolescents: a Randomized, Double-Blind, and Placebo-Controlled Study.

Several studies suggest that probiotics might be useful in the management of atopic dermatitis (AD). However, the efficacy and comparison between both the administration of viable and non-viable probiotics on alleviation of AD is not well studied. Therefore, the purpose of this study was to evaluate the effect of L. sakei proBio65 live and dead cells when administered (1 × 1010 cells/day) for 12 weeks to children and adolescents (aged 3 to 18) with atopic dermatitis. In this randomized double-blind, placebo-controlled study, ninety patients were recruited and randomly allocated to either the L. sakei proBio65 live cells, L. sakei proBio65 dead cells, or placebo groups. Assessment of efficacy was based on the change in SCORing Atopic Dermatitis (SCORAD) score, Investigators Global Assessment (IGA) score, serum inflammatory markers such as the serum eosinophil (count), IgE, eosinophil cationic protein (ECP), CCL17 (thymus and activation-regulated chemokine [TARC]), and CCL27 (cutaneous T cell-attracting chemokine [CTACK]), and changes in skin condition (moisture and sebum) at baseline, week 6 and week 12. The SCORAD total score decreased in the live cells (p = 0.0015) and dead cell group (p = 0.0017) from the baseline after 12 weeks, whereas there were no significant changes in the placebo group when compared with baseline. The skin sebum content increased in both the live cell (p < 0.0001) and the dead cell group (p < 0.0001), suggesting potential improvements in skin barrier functions. Current data suggested a positive improvement in alleviation of AD symptoms upon oral administration of L. sakei proBio65 in both viable and non-viable forms.

Effect of a bioactive product SEL001 from Lactobacillus sakei probio65 on gut microbiota and its anti-colitis effects in a TNBS-induced colitis mouse model.

This study underpins the therapeutic potential of SEL001, a bioactive product isolated from Lactobacillus sakei probio65, in terms of its anti-inflammatory properties and its effect on gut-microbiota in a TNBS-induced ulcerative colitis mouse model. Ulcerative colitis was developed in mice by intra rectal administration of trinitrobenzene sulfonic acid. Bioactive product SEL001 (50 mg/kg b.w.) was administered orally. Myeloperoxidase activity was measured using 3,3', 5,5'-tetramethylbenzidine. The entire colon was sampled for post-mortem clinical assessment. Colonic injury was assessed through histological and histomorphometric examinations. The 454 pyrosequencing and QIIME pipeline were used for gut microbiota analysis and statistical analysis were conducted using R. mRNA extraction from colon tissue and RT-PCR approaches were employed to determine the changes in the level of specific biomarker genes associated with UC. The results depict that SEL001 significantly lowered pro-inflammatory cytokines, including CD4, TNF-α, and interleukin-6. Examination of clinical and histopathological traits revealed that SEL001 was effective and potent in reducing the inflammatory signatures of UC to a similar extent as did by the standard drug mesalamine (5-ASA). Pyro-sequencing 16S data revealed that the reduction in the major member of phylum Firmicutes, which has been previously associated with a higher risk of UC. The SEL001, an anti-inflammatory bioactive product originated from a probiotic strain L. sakei probio65 could be an alternative therapeutic agent for treatment of UC.

Characterization and pharmacological potential of Lactobacillus sakei 1I1 isolated from fresh water fish Zacco koreanus.

BACKGROUND: There are still a large variety of microorganisms among aquatic animals which have not been explored for their pharmacological potential. Hence, present study was aimed to isolate and characterize a potent lactic acid bacterium from fresh water fish sample Zacco koreanus, and to confirm its pharmacological potential. METHODS: Isolation of lactic acid bacteria (LAB) from fresh water fish samples was done using serial dilution method. Biochemical identification and molecular characterization of selected LAB isolate 1I1, based on its potent antimicrobial efficacy, was accomplished using API kit and 16S rRNA gene sequencing analysis. Further, 1I1 was assessed for α-glucosidase and tyrosinase inhibitory potential as well as antiviral efficacy against highly pathogenic human influenza virus H1N1 using MDCK cell line in terms of its pharmacological potential. RESULTS: Here, we first time report isolation as well as biochemical and molecular characterization of a lactic acid bacterium Lactobacillus sakei 1I1 isolated from the intestine of a fresh water fish Z. koreanus. As a result, L. sakei 1I1 exhibited potent antimicrobial effect in vitro, and diameter of zones of inhibition of 1I1 against the tested pathogens was found in the range of 13.32 ± 0.51 to 23.16 ± 0.32 mm. Also L. sakei 1I1 at 100 mg/ml exhibited significant (p < 0.05) α-glucosidase and tyrosinase inhibitory activities by 60.69 and 72.59%, in terms of its anti-diabetic and anti-melanogenic potential, respectively. Moreover, L. sakei 1I1 displayed profound anti-cytopathic effect on MDCK cell line when treated with its ethanol extract (100 mg/ml), confirming its potent anti-viral efficacy against H1N1 influenza virus. CONCLUSIONS: These findings reinforce the suggestions that L. sakei 1I1 isolated from the intestine of fresh water fish Z. koreanus might be a candidate of choice for using in pharmacological preparations as an effective drug.